Drug Trial News

RSS

Clinical trial tests experimental stem cell treatment against best available drugs for MS

A clinical trial has begun testing an experimental stem cell treatment against the best available biologic therapies for severe forms of relapsing multiple sclerosis.

7 Jan 2020

AI Therapeutics reports considerable progress on LAM-001 and LAM-004 clinical trials

AI Therapeutics is a clinical-stage biopharmaceutical company that has created an artificial intelligence-driven drug development platform for matching drugs to new indications.

7 Jan 2020

New antibody-drug conjugate shows promising activity in salivary gland tumors

The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors, according to data published in the Annals of Oncology.

7 Jan 2020

Phase II case-control trial initiated for four types of terminal cancers

The Alexandrov National Cancer Centre begins phase II case-control clinical trial of its immuno-oncology agent, Elenagen.

7 Jan 2020

Drug trial seeking treatment option for hyperphagia in patients with Prader-Willi Syndrome

One in every 15,000 children is affected by Prader-Willi syndrome (PWS), a complex, genetic endocrine condition caused by a disorder of chromosome 15. It's non-inheritable, meaning the condition isn't passed down from a family member.

3 Jan 2020

Data results of NCI-MATCH trial in tumors with DNA mismatch repair deficiencies

Final results are published from an evaluation of 42 patients treated with the immune checkpoint inhibitor nivolumab in the large multi-arm precision medicine trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131).

20 Dec 2019

FDA approves new drug to treat adults with advanced urothelial or bladder cancer

The U.S. Food & Drug Administration granted accelerated approval to the drug enfortumab vedotin (EV) to treat adult patients with advanced urothelial or bladder cancer.

19 Dec 2019

New standards needed for improving the design of clinical trials for MS patients

How can the perspectives of patients with multiple sclerosis (MS) be given more consideration in clinical trials? This question was investigated and corresponding recommendations were developed by a working group of the Drug Commission of the German Medical Association, the Charité University Hospital Berlin, and the Institute for Quality and Efficiency in Health Care.

17 Dec 2019

Novel drug shows efficacy against advanced ROS1 and NTRK fusion-positive NSCLC

Pooled analysis of three phase 1 and 2 clinical trials published online ahead of print in the journal Lancet Oncology show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC).

14 Dec 2019

10-year results from clinical trial of extended letrozole therapy for women with HR+ breast cancer

In the updated results from NRG Oncology/NSABP B-42 trial through 10 years of observation, extending letrozole therapy for additional five years after five years of adjuvant endocrine therapy resulted in a statistically significant improvement in the 10-year disease-free survival (DFS) of postmenopausal women with hormone-receptor-positive breast cancer.

12 Dec 2019

Anastrozole can be preventive drug-of-choice for women with high breast cancer risk

The Queen Mary University of London professor leading an international breast cancer study says anastrozole - rather than tamoxifen - should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease.

12 Dec 2019

Treatment combination improves survival in advanced HER2-positive breast cancer patients

Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial.

11 Dec 2019

UMSOM researchers to test the safety, tolerability of prototype Shigella-ETEC vaccine

Each year, millions of people contract serious diarrheal illnesses typically from contaminated food and water. Among the biggest causes of diarrheal diseases are the bacteria Shigella and enterotoxigenic Escherichia coli, and researchers at the University of Maryland School of Medicine are testing a vaccine designed to offer protection against these serious pathogens.

10 Dec 2019

Clinical trial eligibility criteria may be excessive, needlessly excluding patients

Federal regulations may keep lung cancer patients out of clinical trials simply because these patients are on medications that might affect the electrical system of the heart. Drilling into the details quickly turns up reasons to think these regulations may be preventing a substantial proportion of patients from participating in clinical trials.

10 Dec 2019

Evaluating safety and efficacy of migraine preventive treatment for children, adolescents

Cephalalgia, the official journal of the International Headache Society, published the article entitled "Cinnarizine and sodium valproate as the preventive agents of pediatric migraine: A randomized double-blind placebo-controlled trial", by Man Amanat, and Mahmoud Reza Ashrafi from the Tehran University of Medical Sciences, Tehran, Iran.

10 Dec 2019

Immunotherapy more effective than chemotherapy for children, young adults with relapsed B-ALL

New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia that has relapsed.

10 Dec 2019

Pairing chemotherapy azacitidine with enasidenib boosts complete remission in AML patients

A multi-institutional, Phase II study led by The University of Texas MD Anderson Cancer Center showed that pairing standard chemotherapy azacitidine (AZA) with a drug called enasidenib (ENA) measurably boosts complete remission in patients newly diagnosed with a specific form of acute myeloid leukemia (AML).

9 Dec 2019

Study shows safety of palbociclib for advanced breast cancer patients with unique gene alteration

Women who receive palbociclib (Ibrance) to treat their advanced breast cancer and have a gene alteration that can lead to a condition known as benign ethnic neutropenia (BEN), can safely receive the drug without major concerns of developing infections associated with neutropenia, or low white blood cell counts, say Georgetown Lombardi Comprehensive Cancer Center researchers.

9 Dec 2019

$Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission$

Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission.

8 Dec 2019

Ibrutinib-based therapy provides superior clinical outcomes in majority of CLL patients

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) today announced results from an extended follow-up analysis of patients in its randomized Phase 3 clinical trial, E1912.

8 Dec 2019

Previous
1
...
92
93
94
95
96
97
98
...
1149
Next

Drug Trial News

Clinical trial tests experimental stem cell treatment against best available drugs for MS

AI Therapeutics reports considerable progress on LAM-001 and LAM-004 clinical trials

New antibody-drug conjugate shows promising activity in salivary gland tumors

Phase II case-control trial initiated for four types of terminal cancers

Drug trial seeking treatment option for hyperphagia in patients with Prader-Willi Syndrome

Data results of NCI-MATCH trial in tumors with DNA mismatch repair deficiencies

FDA approves new drug to treat adults with advanced urothelial or bladder cancer

New standards needed for improving the design of clinical trials for MS patients

Novel drug shows efficacy against advanced ROS1 and NTRK fusion-positive NSCLC

10-year results from clinical trial of extended letrozole therapy for women with HR+ breast cancer

Anastrozole can be preventive drug-of-choice for women with high breast cancer risk

Treatment combination improves survival in advanced HER2-positive breast cancer patients

UMSOM researchers to test the safety, tolerability of prototype Shigella-ETEC vaccine

Clinical trial eligibility criteria may be excessive, needlessly excluding patients

Evaluating safety and efficacy of migraine preventive treatment for children, adolescents

Immunotherapy more effective than chemotherapy for children, young adults with relapsed B-ALL

Pairing chemotherapy azacitidine with enasidenib boosts complete remission in AML patients

Study shows safety of palbociclib for advanced breast cancer patients with unique gene alteration

Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

Ibrutinib-based therapy provides superior clinical outcomes in majority of CLL patients

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Latest News